Emyria Ltd has released a press release.
Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Emyria
- MDMA-analogues Show Promise for Parkinsons Disease
- Emyria Engages Calvert Labs for Preclinical CBD studies
- Emyria Appoints Expert Neuropharmacologist for MDMA Program
- Emyria Executes Pure CBD Agreement with AltaSciences
- Emyria to Develop Novel Psychedelics Pipeline with UWA
Later from Emyria
- Novel MDMA Analogue Screening Program Advanced
- Emyria selected to join Palantirs Foundry Builders Program
- MDMA Analogue Development Milestone
- Emyria Welcomes Tattarang as Strategic Investor
- Emyria receives $1,162,000 R&D Tax Incentive Refund
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria